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Abstract: Chemotherapeutic agents such as doxorubicin may negatively affect long-term brain
functioning in cancer survivors; neuroinflammation may play a causal role. Dietary approaches
that reduce inflammation, such as lowering sucrose and increasing eicosapentaenoic acid plus
docosahexaenoic acid (EPA + DHA), may attenuate chemotherapy-induced neuroinflammation and
synaptic damage, thereby improving quality of life. Ovariectomized, C57BL/6 mice were assigned
to a chemotherapy (9 mg/kg doxorubicin + 90 mg/kg cyclophosphamide) or vehicle two-injection
regimen, with injections two and four weeks after starting diets. In Study 1, mice received low sucrose
diets with EPA + DHA or No EPA + DHA for four to six weeks; tissues were collected four, seven, or
14 days after the second injection. Compared to vehicle, chemotherapy increased pro-inflammatory
cytokine IL-1β at day seven in the cortex and hippocampus, and reduced gene expression of synaptic
marker Shank 3 at all timepoints in cortex, while EPA + DHA increased expression of Shank 3.
In Study 2, high or low sucrose/EPA + DHA or No EPA + DHA diets were fed for five weeks;
tissues were collected ten days after the second injection. Among chemotherapy-treated mice, brain
DHA was higher with low sucrose feeding. Furthermore, low sucrose increased gene expression
of Shank 1, while EPA + DHA increased expression of Shank 3 and reduced protein concentrations
of pro-inflammatory markers IL-5, IL-6 and KC/GRO in the cortex, but not the hippocampus. Low
sucrose, EPA + DHA diets may attenuate neuroinflammation and synaptic damage induced by
doxorubicin-based chemotherapy in specific brain regions.
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1. Introduction
Chemotherapy treatment for breast cancer has contributed to improved survival rates for millions
of women [1]. However, chemotherapeutic agents, such as doxorubicin, which are frequently used to
treat breast cancer and other solid tumors, have several detrimental side effects, including toxicities
that affect normal functioning of the brain [2]. Studies report cognitive side effects in up to 75% of
individuals treated with chemotherapy for cancer [1]; indeed, cognitive deficits negatively impact
quality of life in nearly 30% of breast cancer survivors [3,4] by interfering with activities of daily living
such as reading, working, and driving [5]. These cognitive deficits may persist for up to 15 years
post-treatment [6], affecting verbal fluency, working memory and processing speed [7]. Common side
effects of chemotherapy not only include cognitive deficits, but other behavioral toxicities such as
sleep disturbances and associated fatigue [8,9], affect disorders [10] and neuropathy [8]. Although
the mechanisms underlying chemotherapy-induced behavioral toxicities have not been conclusively
established, research suggests that neuroinflammation, oxidative stress and their effects on neuronal
structure and function may play a key role [8,9,11–14].
Dietary approaches that reduce inflammation and oxidative stress are potential strategies for
alleviating negative cognitive outcomes associated with chemotherapy. The omega-3 polyunsaturated
fatty acids (n-3 PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), found
primarily in fish, have well-established anti-inflammatory properties [15]. Recent animal research
found that administration of EPA and DHA concurrently with doxorubicin chemotherapy
reduced neuroinflammation, oxidative stress, and neural apoptosis, and prevented depressive-like
symptoms [16]. In lung cancer patients undergoing chemotherapy, EPA and DHA supplementation
reduced plasma markers of inflammation and oxidative stress compared to placebo [17]. In breast
cancer survivors, dietary EPA and DHA were associated with lower inflammation after 24 weeks
of aromatase-inhibitor treatment [18]. Incorporation of DHA in particular, into plasma membranes,
was associated with improved overall survival in women with advanced metastatic breast cancer
during doxorubicin-based chemotherapy [19].
In contrast to the potential benefits of EPA and DHA on inflammation and behavioral outcomes,
high amounts of dietary added sugars may act independently to promote cognitive deficits [20] and
systemic inflammation [21], or interact with n-3 PUFAs to diminish their anti-inflammatory actions [22]
and cause changes in brain n-3 PUFA metabolism [23]. Evidence from a rodent model of metabolic
syndrome suggests that a diet rich in n-3 PUFAs is effective at alleviating some of the deleterious
outcomes of high added sugar consumption on memory [20]. Whether chemotherapy-induced
physiological changes in the brain are amplified by high sugar intake, or if dietary enrichment
with n-3 PUFAs can attenuate neuroinflammation, oxidative stress, and structural changes in the
context of a high sugar diet, has not been previously studied. To address this translationally important
research gap, we undertook several experiments to investigate these interactions and underlying
mechanisms using a postmenopausal mouse model of chemotherapy to mirror treatment commonly
administered to breast cancer patients. We hypothesized that a low sucrose, high EPA + DHA
diet would protect the brain from the neuroinflammatory and synaptic damage associated with
doxorubicin-based chemotherapy.
2. Materials and Methods
2.1. Animals and Treatments
These studies were conducted in accordance with the National Institute of Health Guide for the
Care and Use of Laboratory Animals and under protocols approved by the Ohio State Institutional
Animal Care and Use Committee. The mice were randomly assigned to groups and all data were
collected by individuals who were uninformed of experimental assignment.
Adult (~8 weeks old) C57BL/6 female mice were purchased from Charles River Laboratories
(Wilmington, MA, USA). Upon arrival, mice were housed in an Association for Assessment and
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Accreditation of Laboratory Animal Care-approved vivarium and acclimated to the facility at a 14:10
light/dark cycle. All animals were provided ad libitum access to standard chow and water. The mice
were ovariectomized using a sterile surgical technique; buprenorphine was provided for analgesia.
One week later, they were weighed, transferred to individual cages, and started on semi-purified diets.
Four modified AIN-76A diets were produced by Research Diets Inc. (Newark, NJ, USA): a 2%
EPA + DHA/Low sucrose diet containing 2% of kcal as EPA + DHA and 9% of kcal as sucrose, a No
EPA + DHA/Low sucrose diet, a No EPA + DHA/High sucrose diet containing 47% kcal as sucrose,
and a 2% EPA + DHA/High sucrose. The diets contained the same total macronutrients, kilocalories,
fiber, vitamins, minerals, and other antioxidants (Supplementary Table S1). Fatty acid composition of
the diets was measured by gas chromatography (Table S2). Diets were stored under refrigeration (4 ◦C)
in the dark to prevent degradation, and were replaced every 3–4 days and food intake was recorded
until completion of each study.
Mice were randomly assigned to the chemotherapy or saline treatment group at the beginning of
each study. They received a total of two tail vein injections of either a cocktail of 9 mg/kg doxorubicin
plus 90 mg/kg cyclophosphamide or sterile isotonic saline vehicle, two and four weeks after beginning
diets. This chemotherapy dose was calculated to be the mouse equivalent of 50% of the typical human
dose based on a body surface area equation [24]. Body weight was recorded prior to each injection.
2.2. Experimental Design
Study 1: Omega-3 and Chemotherapy Timecourse Experiment. One week after ovariectomy,
mice (n = 60/diet) were randomized to No EPA + DHA/Low sucrose or 2% EPA + DHA/Low
sucrose diets and the injection regimen described above. Mice were sacrificed and tissues were
collected 4, 7 or 14 days after the second injection to determine changes in markers of central and
peripheral inflammation.
Study 2: Sucrose, Omega-3, Chemotherapy and Brain Physiology Experiment. One week after
ovariectomy, mice (n = 26/diet) were randomized to one of four diets (2% EPA + DHA/Low sucrose
diet, No EPA + DHA/Low sucrose diet, No EPA + DHA/High sucrose diet, and 2% EPA + DHA/High
sucrose diet). As in Study 1, two weeks after beginning diets, mice received the first injection of
chemotherapy or vehicle, followed by a second injection two weeks later. In this study, tissues were
collected at only one time point, ten days after the second injection.
2.3. Blood and Tissue Collection
Following blood collection from the submandibular vein, mice were injected with euthasol
(270 mg/kg). Deeply anesthetized mice were perfused transcardially with 0.1 M PBS; then, brain
was dissected and one hemisphere was flash frozen and stored at −80 ◦C for fatty acid and oxidative
stress analysis, while the other hemisphere was stored in RNA-Later Reagent (Qiagen, Germantown,
MD, USA) for protein and/or gene expression analysis.
2.4. RNA Preparation and Quantitative Polymerase Chain Reaction
Messenger RNA (mRNA) and protein were extracted from the hippocampus and cortex using
TriZol reagent (Life Technologies, Thermo Fischer Scientific Inc., Waltham, MA, USA) and following
the manufacturer’s instructions. Following the chloroform incubation and centrifugation RNA was
extracted from the aqueous phase, while protein was extracted from the organic phase. mRNA quality
and quantity were determined using a spectrophotometer (NanoDrop, Thermo Fisher Scientific Inc.).
Then, cDNA was synthesized using M-MLV reverse transcription and diluted 1:10 for subsequent
qPCR. mRNA concentrations of pro-inflammatory markers such as cytokines and nuclear factor κ-β
(Nfκ-β), and synaptic proteins such as SH3 and multiple ankyrin repeat domains protein 1 (Shank 1) and
3 (Shank 3), were determined using a spectrophotometer (NanoDrop, Thermo Fischer Scientific Inc.).
The qPCR reaction was performed using endogenous control eukaryotic 18S, probes from Applied
Biosystems (see Table S3 for the list of primers), and Taqman Advanced Universal Master Mix (all
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from Life Technologies), on an ABI 7000 Sequencing Detection System. Relative gene expression was
quantified by normalizing the target gene with endogenous control 18S.
2.5. Cytokine and Chemokine Protein Assays
Serum, hippocampal and cortical samples were analyzed for protein levels of tumor necrosis
factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-10 (IL-10), IL-12p70, IL-1β, IL-2, IL-4, IL-5, IL-6, and
keratinocyte chemoattractant/human growth-regulated oncogene (KC/GRO, also known as CXCL1)
using a multiplex assay (V-Plex proinflammatory panel 1, Meso-Scale Discovery, Rockville, MD, USA).
2.6. Fatty Acid Analysis
Total lipids from one brain hemisphere were extracted [25] and methylated [26], and analysis
of fatty acid methyl esters was completed by gas chromatography as previously described [27].
Retention times were compared to authentic standards for fatty acid methyl esters (Nu-Check Prep
Inc., Elysian, MN, USA and Matreya, Inc., Pleasant Gap, PA, USA) and fatty acids were reported as
percent of total identified.
2.7. Lipid Peroxidation and Oxidative Stress Assays
Total protein was extracted from brain tissue lysate using a Pierce BCA Protein Assay Kit (Fisher
Scientific, Waltham, MA, USA) and quantified by spectrophotometry. Following protein extraction,
brain lysates containing PBS and protease inhibitor were derivatized for carbonyl groups using
the Oxyblot Kit (EMD Millipore, Billerica, MA, USA) according to the manufacturer’s instruction.
Proteins were loaded on a 12% SDS-PAGE and electrotransferred to a nitrocellulose membrane
(Bio-Rad Laboratories, Hercules, CA, USA). Membranes were incubated in blocking buffer (1% BSA
in 1× PBS-T) at room temperature for 1 h followed by incubation overnight at 4 ◦C with the
primary Rabbit Anti-DNP antibody, then incubation with secondary antibodies (Goat Anti-Rabbit
IgG; HRP-conjugated) at room temperature for 1 h. Bands were detected by chemiluminescence using
Odyssey® Fc Imaging System (LI-COR Biosciences, Lincoln, NE, USA).
As a marker of lipid peroxidation, levels of 4-hydroxynonenal–histidine (4-HNE) protein adducts
in brain were assayed using the Oxiselect HNE–His Adduct ELISA Kit (EMD Millipore, Billerica,
MA, USA) and normalized to protein levels. Oxidative stress was assayed in brain lysates derivatized
for carbonyl groups using the Oxyblot Kit (EMD Millipore, Billerica, MA, USA). Superoxide dismutase
(SOD) was measured using an activity assay (Cell Biolabs Inc, San Diego, CA, USA). Brain samples
were prepared by homogenizing in lysis buffer (10 mM Trish, 150 mM NaCl, 0.1 mM EDTA) and
centrifuging at 12,000× g for 10 min. The supernatant was extracted and plated with standards
according to the kit instructions. The absorbance was read at 490 nm and data is expressed as percent
inhibition of superoxide anions.
2.8. Statistical Analysis
Grubbs test was used to detect outliers within groups; data values corresponding to a Z-score > 2
were removed prior to completing statistical analysis and graphing. For outcome measures where
a large fraction of samples (>25%) were below the detection limit, no analysis was completed.
Gene expression, protein, fatty acids, peroxidation, oxidative stress, food intake, and behavior data
were analyzed using three-way analysis of variance (ANOVA). Factors for study 1 were injection type
(chemo, vehicle), omega-3 (2% EPA + DHA, No EPA + DHA), and day (4, 7, 14 days post-injection).
Factors for study 2 were injection type (chemo, vehicle), sucrose (high, low), and omega-3 (2% EPA
+ DHA, No EPA + DHA). Repeated measures ANOVA was used to evaluate body weight changes.
When the overall ANOVA F-test was significant (p < 0.05), significant interactions and lower order
terms were examined and graphed, and pairwise comparisons were made by comparing the groups
within a single variable (e.g., vehicle versus chemo and 2% EPA + DHA versus No EPA + DHA).
Results are reported as group means averaged over any factors not involved in the interaction term
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or main effect. Statistical analysis was completed with SAS software version 9.4 (Cary, NC, USA).
In graphs, data are presented as mean ± standard error of the mean (SEM).
3. Results
3.1. Effects of Omega-3 Fatty Acids and Chemotherapy on Food Intake and Body Weight
In study 1, there was a significant effect of diet on cumulative food intake (p < 0.001) such that
mice in the No EPA + DHA groups (both chemotherapy and vehicle) averaged 6% greater food intake
than mice in the 2% EPA + DHA/chemotherapy group (all p < 0.05) at end of the study (Table S4).
There were no significant differences in body weight between diet groups at baseline, day 14 or day
28 (all p > 0.05). However, there was a significant injection by day effect on body weight (p < 0.0001);
specifically, mice in the chemotherapy groups lost a mean of 0.72 ± 1.03 g of body weight from first
injection to second injection, while mice in vehicle groups gained a mean of 0.30 ± 1.57 g. (Table S4).
3.2. Effects of Omega-3 Fatty Acids and Chemotherapy on Serum Protein Concentrations of Cytokines and
Chemokines over Time
Protein concentrations for IL-1β, IL-5, IL-6, KC/GRO and TNF-α were measured; IFN-γ, IL-10,
IL-12p70, IL-2 and IL-4 were not analyzed because >25% of samples were below the detection limits in
study 1. We observed differences in the cytokine pattern between chemotherapy and vehicle groups
over time, as has been reported in other models of inflammation [28,29]. We observed an initial rise in
KC/GRO, also known as CXCL1, a chemokine responsible for recruitment of peripheral mononuclear
cells to the site of inflammation [30]. There was an injection by day interaction (Figure 1A; p < 0.05),
such that the chemotherapy group had higher mean KC/GRO than the vehicle group 4 days after
second injection only (p < 0.001). There was also a significant n-3 PUFAs by day interaction on
KC/GRO (Figure 1B; p < 0.05) such that in the EPA + DHA group, KC/GRO concentration decreased
over time, whereas in the No EPA + DHA group it decreased from 4 to 7 days post-chemotherapy
and then increased from 7 to 14 days. Serum TNF-α varied significantly among groups (Figure 1C;
p < 0.01). There was a significant injection by tissue collection day interaction (p < 0.05) on serum
TNF-α; specifically, TNF-α concentration increased over time in the chemotherapy group. By day 14,
the mean for the chemotherapy group was significantly higher than the vehicle group (p < 0.05). IL-6
was significantly higher among the chemotherapy than vehicle groups at all time points (Figure 1D;
p < 0.0001), suggesting a sustained effect of chemotherapy on this cytokine, as has been noted in
breast cancer patients undergoing doxorubicin plus cyclophosphamide treatment [31]. Altogether,
these findings suggest that chemotherapy leads to systemic inflammation, an effect that can be partly
moderated by n-3 PUFAs.
Nutrients 2018, 10, 2004 6 of 18
Nutrients 2018, 10, x FOR PEER REVIEW  6 of 18 
 
 
Figure 1. Serum cytokines and chemokines in mice receiving 2% EPA + DHA or No EPA + DHA diets 
and vehicle or chemotherapy 4, 7, or 14 days (D4, D7, D14) after second injection (Study 1). Proteins 
concentrations measured by multiplex ELISA assay. Data (means ± SEM, n = 8–12 mice per group) 
were analyzed by 3-way ANOVA. (A) Injection by day interaction effect on keratinocyte 
chemoattractant/human growth-regulated oncogene (KC/GRO). (B) Diet by day interaction effect on 
KC/GRO. (C) Injection by day interaction effect on tumor necrosis factor α (TNF-α). (D) Main effect 
of injection on serum Interleukin 6 (IL-6). 
3.3. Effects of Omega-3 Fatty Acids and Chemotherapy on Gene Expression of Cytokines, Chemokines, and 
Shank in the Brain over Time 
In study 1, cortex gene expression of Tnf-α (p = 0.05) and Il-1β (p < 0.01) varied significantly 
among the groups. No significant effects of EPA + DHA diets were found. However, there was an 
injection by day interaction on Tnf-α (Figure 2A; p < 0.05): although Tnf-α remained relatively 
consistent over time in the chemotherapy group, Tnf-α was elevated in the vehicle group relative to 
the chemotherapy group 7 days post-injection (p < 0.05). This might result from a negative feedback 
loop in cytokine signaling [32]. Cortical Il-1β gene expression also exhibited an injection by day 
interaction (Figure 2B; p < 0.05). At 7 days post-injection, the chemotherapy group had significantly 
higher Il-1β expression than the vehicle treated group (p < 0.001). There were no significant group 
differences in expression of Il-6 or Nfκ-β (p > 0.05 for both). 
There were no significant group differences in hippocampal gene expression of Tnf-α, Il-6, or 
Nfκ-β (p > 0.05 for all). However, results differed by group for Il-1β (p < 0.01); there was an interaction 
between the injection and day on hippocampal Il-1β (Figure 2C; p < 0.001). At 7 days post-injection, 
the chemotherapy mice expressed significantly higher Il-1β than the vehicle treated mice (p < 0.0001). 
These data suggest that, of the time points measured, 7 days after the second chemotherapy injection 
was the most neuroinflammatory, and neuroinflammation was mediated primarily through IL-1β, as 
peripheral TNF-α was elevated at this time point (Figure 1C), but chemotherapy did not increase 
gene expression of TNF-α in the brain at that time (Figure 2A). 
A
C
B
D
i r Seru cytokines and chemokines in mic r ceiving 2% EPA + DHA or No EPA + DHA
diets and vehicle or c emotherapy 4, 7, or 14 days (D4, D7, D14) after second injection (Study 1).
Protei s concentrations measured by multiplex ELISA assay. Data (means ± SEM, n = 8–12 mice
per group) w re analyzed by 3-way NOVA. (A) Injection by day interaction effect on kerati c t
ttractant/ t - l t ( ). ( ) i t i t ti ff t
. ( ) I j ti y day interaction effect on tumor necrosis factor α (TNF-α). (D) Main eff ct of
injection serum Interleukin 6 (IL-6).
3.3. Effects of Omega-3 Fatty Acids and Chemotherapy on Gene Expression of Cytokines, Chemokines, and
Shank in the Brain over Time
In study 1, cortex gene expression of Tnf-α (p = 0.05) and Il-1β (p < 0.01) varied significantly among
the groups. No significant effects of EPA + DHA diets were found. However, there was an injection
by day interaction on Tnf-α (Figure 2A; p < 0.05): although Tnf-α remained relatively consistent over
time in the chemotherapy group, Tnf-α was elevated in the vehicle group relative to the chemotherapy
group 7 days post-injection (p < 0.05). This might result from a negative feedback loop in cytokine
signaling [32]. Cortical Il-1β gene expression also exhibited an injection by day interaction (Figure 2B;
p < 0.05). At 7 days post-injection, the chemotherapy group had significantly higher Il-1β expression
than the vehicle treated group (p < 0.001). There were no significant group differences in expression of
Il-6 or Nfκ-β (p > 0.05 for both).
There were no significant group differences in hippocampal gene expression of Tnf-α, Il-6, or Nfκ-β
(p > 0.05 for all). However, results differed by group for Il-1β (p < 0.01); there was an interaction
between the injection and day on hippocampal Il-1β (Figure 2C; p < 0.001). At 7 days post-injection,
the chemotherapy mice expressed significantly higher Il-1β than the vehicle treated mice (p < 0.0001).
These data suggest that, of the time points measured, 7 days after the second chemotherapy injection
was the most neuroinflammatory, and neuroinflammation was mediated primarily through IL-1β,
as peripheral TNF-α was elevated at this time point (Figure 1C), but chemotherapy did not increase
gene expression of TNF-α in the brain at that time (Figure 2A).
Gene expression of Shank 3, a postsynaptic density protein that participates in synapse formation
and dendritic spine maturation [33], was examined in the hippocampus and cortex. Hippocampal
Shank 3 gene expression remained constant throughout the experimental groups and time points
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investigated (data not shown; p > 0.05). However, in the cortex, the protective effect of EPA and
DHA was demonstrated as Shank 3 gene expression was significantly higher for 2% EPA + DHA
groups, irrespective of injection treatment or day of tissue collection (Figure 2D; p < 0.0001). These
data suggest that in the presence or absence of a chemotherapy-induced inflammatory environment,
n-3 administration may facilitate synapse formation in the cortex.Nutrients 2018, 10, x FOR PEER REVIEW  7 of 18 
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3.5. Effects of Sucrose, Omega-3 Fatty Acids, and Chemotherapy on Brain Fatty Acids
In study 2, analysis of brain fatty acids by gas chromatography revealed significant differences in
numerous n-3 and n-6 fatty acids (Table S6). As expected, the brain n-3 PUFA, EPA (C20:5n-3) and
docosapentaenoic acid n-3 (C22:5n-3), were significantly higher (p < 0.0001 for both) and the n-6 fatty
acids, li oleic acid (C18:2n-6), arachidonic acid (C20:4 -6) and docosat traenoic acid (C22:4n-6) were
significantly lower (all p < 0.001) in the 2% EPA + DHA compared to No EPA + DHA diet groups.
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Additionally, there was a significant main effect of sucrose on linoleic acid (p < 0.05) such that brain
linoleic acid was significantly higher in low sucrose versus high sucrose groups. There was a significant
interaction of injection by n-3 diet group (p < 0.05, Figure 3A), such that brain DHA (C22:6n-3) was
significantly higher in mice fed 2% versus No EPA + DHA diets in both the chemotherapy (p < 0.01)
and vehicle (p < 0.0001) groups, but the difference was significantly larger for vehicle treated groups
(p < 0.05). Interestingly, there was a significant injection by sucrose interaction on DHA (Figure 3B;
p < 0.05) such that brain DHA was significantly higher in the mice fed low sucrose versus high sucrose
diets in the chemotherapy group (p < 0.01) but not in the vehicle group (p > 0.05).
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3.6. Effects of Sucrose, Omega-3 Fatty Acids, and Chemotherapy on Serum Protein Concentrations of Cytokines
and Chemokines
In the serum, protein concentrations of TNF-α, IL-1β, IL-6, IFN-γ, IL-5, KC/GRO, IL-10, and
IL-2 were analyzed (Table 1); IL-12p70 and IL-4 were not analyzed because >25% of samples were
below the detection limits in study 2 (data not shown). Serum concentrations of IL-10, IL-2 and
KC/GRO did not vary across experimental groups (p > 0.05 for all). TNF-α (p ≤ 0.01), IL-6 (p < 0.0001),
IFN-γ (p ≤ 0.01), and IL-5 (p < 0.0001) varied among the experimental groups, displaying an injection
mediated main effect where the chemotherapy mice exhibited increased cytokine expression relative
to the vehicle mice. IL-1β also varied significantly between groups (p < 0.0001), with a significant
three-way interaction between chemotherapy, sucrose and EPA + DHA (Figure 4; p < 0.01). Among
the chemotherapy groups, the mice receiving a low sucrose and No EPA + DHA diet expressed
significantly lower IL-1β than all other groups (p < 0.05 for all comparisons). Among the vehicle
treated mice, there were no significant differences (p > 0.05 for all comparisons). Taken together,
these data demonstrate chemotherapy-induced inflammation in the periphery, which can be partially
attenuated by low sucrose feeding in the absence of n-3 enrichment.
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Table 1. Protein concentrations of inflammatory and synaptic markers in serum, the hippocampus, and the cortex in mice receiving various combinations of omega-3
and sucrose diets and two injections of chemotherapy or vehicle (Study 2).
Chemotherapy Vehicle
2% EPA + DHA No EPA + DHA 2% EPA + DHA No EPA + DHA 2% EPA + DHA No EPA + DHA 2% EPA + DHA No EPA + DHA
Low Sucrose Low Sucrose High Sucrose High Sucrose Low Sucrose Low Sucrose High Sucrose High Sucrose
Serum
IFN-γ # 0.78 (0.33) 0.73 0.44 0.62 0.18 0.60 0.27 0.44 0.16 0.43 0.24 0.54 0.26 0.41 0.30
IL-10 9.0 (4.5) 7.7 (1.7) 8.1 (2.8) 9.0 (2.7) 7.7 (1.2) 9.0 (3.5) 7.7 (1.8) 7.3 (3.2)
IL-1b ˆ 1.6 (0.56) 0.91 (0.62) 1.3 (0.50) 1.6 (0.52) 0.48 (0.24) 0.36 (0.14) 0.67 (0.21) 0.46 (0.33)
IL-2 1.3 (1.6) 1.5 (0.88) 1.1 (0.55) 1.0 (0.38) 0.60 (0.38) 0.87 (0.50) 0.52 (0.24) 0.73 (0.26)
IL-5 # 9.1 (6.1) 9.5 (6.9) 8.5 (4.9) 10.1 (4.4) 2.7 (1.1) 2.7 (1.4) 1.9 (0.57) 2.9 (1.2)
IL-6 # 16.7 (7.4) 21.1 (16) 16.7 (7.1) 19.2 (5.5) 4.0 (2.6) 4.5 (2.9) 3.6 (2.0) 2.1 (2.0)
KC/GRO 73.6 (26) 85.6 (34) 84.6 (20) 90.5 (21) 94.0 (19) 94.1 (23) 100.8 (12) 95.6 (16)
TNF-a # 10.3 (2.2) 11.8 (5.5) 11.4 (3.6) 11.1 (2.2) 7.2 (2.4) 7.5 (2.5) 8.5 (2.1) 9.4 (2.5)
Hippocampus
IL-10 1.5 (0.55) 1.5 (0.59) 0.98 (0.51) 1.3 (0.75) 0.86 (0.53) 1.09 (0.76) 1.1 (0.57) 0.74 (0.85)
IL-5 #,Ω 1.2 (0.37) 1.2 (0.43) 1.1 (0.39) 0.98 (0.32) 1.0 (0.33) 0.74 (0.18) 1.1 (0.42) 0.91 (0.23)
IL-6 #,Ω 19.0 (4.2) 18.7 (5) 18.5 (5.5) 16.1 (3.8) 17.4 (4.1) 12.9 (2.5) 17.2 (5.1) 15.1 (3.0)
Cortex
IFN-γ 0.088 (0.052) 0.161 (0.086) 0.100 (0.094) 0.108 (0.061) 0.132 (0.099) 0.088 (0.049) 0.115 (0.068) 0.073 (0.031)
IL-10 1.3 (0.67) 1.7 (0.88) 1.1 (0.72) 1.4 (0.45) 1.2 (0.35) 1.2 (0.55) 1.3 (0.65) 1.1 (0.58)
IL-12 13 (7.0) 18 (9.9) 12 (4.9) 15 (8.0) 13 (9.2) 15 (4.0) 14 (4.9) 15 (3.5)
IL-1b 0.21 (0.13) 0.28 (0.15) 0.43 (0.55) 0.23 (0.07) 0.28 (0.35) 0.29 (0.13) 0.26 (0.12) 0.40 (0.25)
IL-2 0.83 (0.33) 0.98 (0.28) 1.22 (1.49) 0.85 (0.26) 1.05 (0.49) 1.12 (0.41) 0.87 (0.30) 0.84 (0.18)
IL-4 0.31 (0.18) 0.55 (0.20) 0.43 (0.16) 0.44 (0.19) 0.37 (0.22) 0.42 (0.17) 0.46 (0.14) 0.51 (0.15)
IL-5 Ω 1.2 (0.23) 1.4 (0.27) 1.1 (0.40) 1.3 (0.28) 1.1 (0.34) 1.4 (0.23) 1.3 (0.30) 1.5 (0.29)
IL-6 Ω 17 (3.3) 20 (3.7) 17 (5.6) 18 (4.0) 16 (4.1) 20 (3.0) 18 (3.3) 21 (4.1)
KC/GRO Ω 0.39 (0.28) 0.80 (0.38) 0.41 (0.25) 0.57 (0.26) 0.46 (0.34) 0.52 (0.25) 0.40 (0.19) 0.43 (0.18)
TNF-a 0.32 (0.17) 0.45 (0.22) 0.26 (0.14) 0.28 (0.09) 0.31 (0.22) 0.35 (0.14) 0.31 (0.18) 0.37 (0.12)
Data are shown as mean (SD), pg/mL; # Significant main effect of injection; p < 0.01; ˆ Significant 3-way interaction effect of injection by sucrose by EPA + DHA; p < 0.01 (See Figure 4);
Ω Significant main effect of EPA + DHA; p < 0.05.
Nutrients 2018, 10, 2004 10 of 18   x FOR PEER REVIEW  10 of  
 
 
Figure 4. Serum IL-1β by group in mice receiving various combinations of omega-3 and sucrose diets 
and two vehicle or chemotherapy injections (Study 2). Proteins measured by multiplex ELISA assay. 
Data (means ± SEM; n = 11–14/group) were analyzed by 3-way ANOVA. Three-way interaction effect 
of injection by sucrose by omega-3 on IL-1b. 
3.7. Effects of Sucrose, Omega-3 Fatty Acids, and Chemotherapy on Protein Concentrations of Cytokines and 
Chemokines in the Brain 
Protein concentrations of IFN-γ, IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-5, IL-6, KC/GRO and TNF-
α were quantified in the hippocampus and cortex in study 2. In the hippocampus data, >25% of 
samples were below detection limits for IFN-γ, IL-12p70, IL-1β, IL-2, IL-4, KC/GRO, and TNF-α, so 
no statistical analysis was completed. IL-10 concentration in the hippocampus did not vary among 
groups ((Table 1); p > 0.05). Hippocampal concentrations of IL-5 and IL-6 displayed similar patterns 
of variation among groups (p < 0.05 for both). The chemotherapy group had elevated IL-5 and IL-6 
relative to the vehicle group (p < 0.05, main effect of injection), and the 2% EPA + DHA group had 
elevated IL-5 and IL-6 relative to the No EPA + DHA group (p < 0.05, main effect of omega-3 for both). 
Contrary to our hypothesis, these findings suggest that the chemotherapy-induced hippocampal 
increase of pro-inflammatory cytokines IL-5 and IL-6 can be exacerbated by n-3 PUFA. 
In the cortex, analysis for all cytokines was completed (Table 1). Cortical IL-5, IL-6, and KC/GRO 
were the only cytokines that varied among groups (p < 0.05 for all). All three cytokines displayed a 
main effect of EPA + DHA (p < 0.01 for all); in contrast to effects of EPA + DHA in the hippocampus, 
the 2% EPA + DHA group had lower IL-5, IL-6 and KC/GRO concentrations relative to the No EPA + 
DHA group, demonstrating that EPA + DHA reduces inflammation in the cortex. Discrepancy 
between the hippocampal and cortical findings supports brain region specific effects of both the diet 
and chemotherapy treatment. 
3.8. Effects of Sucrose, Omega-3 Fatty Acids, and Chemotherapy on Gene Expression of Inflammatory and 
Synaptic Markers in the Brain 
Although Nf-κβ did not vary appreciably in the chemotherapy treated mice (Figure 5A), among 
mice fed the low sucrose diets, Nf-κβ was elevated in chemotherapy relative to vehicle treated mice 
(p < 0.05); in contrast, among the high sucrose diets, the difference trended in the opposite direction 
(p = 0.052). Mice fed No EPA + DHA/High sucrose exhibited increased Nf-κβ relative to mice fed a 
No EPA + DHA/Low sucrose (Figure 5B; p < 0.0001). Among the 2% EPA + DHA diet groups, sucrose 
did not influence the hippocampal expression of Nf-κβ (p > 0.05). In the cortex, gene expression of 
Tnf-α, Il-1β, Il-6, and Nf-κβ did not vary among the experimental groups (p > 0.05 for all; Table 2). 
These changes in Nf-κβ suggest that low sucrose consumption can attenuate neuroinflammation in 
the hippocampus in the absence of chemotherapy and dietary EPA + DHA. 
The postsynaptic density protein, Shank 1, varied significantly among experimental groups with 
a significant interaction between injection and sucrose (Figure 6; p < 0.0001). Among the low sucrose 
groups, the chemotherapy treated mice exhibited reduced Shank 1 expression relative to the vehicle 
mice (p < 0.0001), but there was no effect of injection among the high sucrose groups (p > 0.05). Shank 
i i
j i t ). r tei s easured by ultiplex ELIS assay.
SE ; n = 1–14/group) were analyzed by 3-way ANOV . Three- i t i
f i j ti - I - .
3.7. Effects of Sucrose, Omega-3 Fatty Acids, and Chemotherapy on Protein Concentrations of Cytokines and
Chemokines in the Brain
Protein concentrations of IFN-γ, IL-10, IL-12p70, IL-1β, IL-2, IL-4, IL-5, IL-6, KC/GRO and
TNF-α were quantified in the hippocampus and cortex in study 2. In the hippocampus data, >25%
of samples were below detection limits for IFN-γ, IL-12p70, IL-1β, IL-2, IL-4, KC/GRO, and TNF-α,
so no statistical analysis was completed. IL-10 concentration in the hippocampus did not vary among
groups ((Table 1); p > 0.05). Hippocampal concentrations of IL-5 and IL-6 displayed similar patterns
of variation among groups (p < 0.05 for both). The chemotherapy group had elevated IL-5 and IL-6
relative to the vehicle group (p < 0.05, main effect of injection), and the 2% EPA + DHA group had
elevated IL-5 and IL-6 relative to the No EPA + DHA group (p < 0.05, main effect of omega-3 for
both). Contrary to our hypothesis, these findings suggest that the chemotherapy-induced hippocampal
increase of pro-inflammatory cytokines IL-5 and IL-6 can be exacerbated by n-3 PUFA.
In the cortex, analysis for all cytokines was completed (Table 1). Cortical IL-5, IL-6, and KC/GRO
were the only cytokines that varied among groups (p < 0.05 for all). All three cytokines displayed a
main effect of EPA + DHA (p < 0.01 for all); in contrast to effects of EPA + DHA in the hippocampus,
the 2% EPA + DHA group had lower IL-5, IL-6 and KC/GRO concentrations relative to the No EPA
+ DHA group, demonstrating that EPA + DHA reduces inflammation in the cortex. Discrepancy
between the hippocampal and cortical findings supports brain region specific effects of both the diet
and chemotherapy treatment.
3.8. Effects of Sucrose, Omega-3 Fatty Acids, and Chemotherapy on Gene Expression of Inflammatory and
Synaptic Markers in the Brain
Although Nf-κβ did not vary appreciably in the chemotherapy treated mice (Figure 5A), among
mice fed the low sucrose diets, Nf-κβ was elevated in chemotherapy relative to vehicle treated mice
(p < 0.05); in contrast, among the high sucrose diets, the difference trended in the opposite direction
(p = 0.052). Mice fed No EPA + DHA/High sucrose exhibited increased Nf-κβ relative to mice fed a No
EPA + DHA/Low sucrose (Figure 5B; p < 0.0001). Among the 2% EPA + DHA diet groups, sucrose
did not influence the hippocampal expression of Nf-κβ (p > 0.05). In the cortex, gene ex ression of
Tnf-α, Il-1β, Il-6, and Nf-κβ did not vary among the experimental groups (p > 0.05 for all; Table 2).
These changes in Nf-κβ suggest that low sucrose consumption can attenuate neuroinflammation in the
hippocampus in the absence of chemotherapy and dietary EPA + DHA.
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The postsynaptic density protein, Shank 1, varied significantly among experimental groups with
a significant interaction between injection and sucrose (Figure 6; p < 0.0001). Among the low sucrose
groups, the chemotherapy treated mice exhibited reduced Shank 1 expression relative to the vehicle
mice (p < 0.0001), but there was no effect of injection among the high sucrose groups (p > 0.05). Shank 1
expression was also significantly lower for both chemotherapy and vehicle receiving mice (p < 0.05 and
p < 0.0001, respectively) receiving high sucrose versus low sucrose diets. These data demonstrate the
protective effect of the low sucrose diet on gene expression of Shank 1. Cortical Shank 3 gene expression
was also variable (Table 2; p < 0.05). It exhibited a main effect of injection (p < 0.05) and EPA + DHA
(p < 0.01). Chemotherapy reduced cortical Shank 3 expression relative to vehicle controls; similar to
Study 1 (Figure 2), the 2% EPA + DHA diet increased the expression relative to the No EPA + DHA diet.
Table 2 shows hippocampal and cortical gene expression of Tnf-α, Il-1β, Il-6 and Nfκ-β, and Shank
3 quantified in study 2. The overall ANOVA F test was not significant for hippocampal Tnf-α, Il-1β,
and Il-6 (all p > 0.05). However, there was significant variation of Nf-κβ (p < 0.0001); there was an
interaction between sucrose and injection (Figure 5A; p < 0.01) and between sucrose and EPA + DHA
(Figure 5B; p < 0.0001) on gene expression of hippocampal Nf-κβ.
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Table 2. Gene expression of inflammatory and synaptic markers in the hippocampus and the cortex in mice receiving various combinations of omega-3 and sucrose
diets and two injections of chemotherapy or vehicle (Study 2).
Chemo Vehicle
2% EPA + DHA No EPA + DHA 2% EPA + DHA No EPA + DHA 2% EPA + DHA No EPA + DHA 2% EPA + DHA No EPA + DHA
Low Sucrose Low Sucrose High Sucrose High Sucrose Low Sucrose Low Sucrose High Sucrose High Sucrose
Hippocampus
TNF-a 2.0 (1.4) 1.3 (0.82) 0.82 (0.6) 2.0 (1.7) 1.2 (1.3) 0.65 (0.51) 1.3 (1.3) 1.2 (0.93)
IL-1b 2.4 (1.9) 1.0 (1.0) 0.66 (0.4) 2.5 (3.1) 1.1 (0.85) 0.4 (0.31) 2.1 (2.9) 1.8 (1.8)
IL-6 1.0 (0.53) 1.12 (0.45) 1.0 (0.47) 1.4 (0.90) 1.22 (0.83) 1.11 (0.60) 0.99 (0.47) 0.99 (0.36)
Nfk-b pi,ω 1.1 (0.31) 0.57 (0.14) 0.82 (0.18) 0.95 (0.25) 0.98 (0.37) 0.41 (0.10) 1.05 (0.31) 1.02 (0.21)
Shank 3 1.0 (0.72) 1.0 0.72 0.73 (0.47) 0.84 (0.46) 1.2 (0.66) 1.1 (0.58) 1.2 (0.76) 1.2 (0.65)
Cortex
TNF-a 1.1 (0.49) 0.66 (0.36) 1.2 (0.49) 0.73 (0.33) 1.0 (0.58) 0.88 (0.34) 1.1 (0.56) 1.1 (0.42)
IL-1b 1.3 (0.66) 0.89 (0.30) 1.4 (0.49) 1.3 (0.77) 1.1 (0.55) 1.1 (0.39) 1.4 (0.85) 1.1 (0.36)
IL-6 1.1 (0.59) 0.82 (0.43) 1.4 (0.66) 1.1 (0.48) 1.2 (0.69) 1.1 (0.28) 1.0 (0.36) 1.1 (0.32)
Nfk-b 0.93 (0.25) 0.91 (0.30) 1.1 (0.27) 0.95 (0.16) 1.0 (0.26) 1.0 (0.32) 1.0 (0.20) 1.0 (0.19)
Shank 3 #,Ω 1.0 (0.20) 0.82 (0.20) 1.0 (0.24) 0.87 (0.12) 1.1 (0.19) 1.0 (0.20) 1.0 (0.20) 0.98 (0.16)
Shank 1 pi 0.71 (0.27) 0.55 (0.20) 0.49 (0.17) 0.29 (0.15) 0.98 (0.55) 1.2 (0.61) 0.61 (0.36) 0.33 (0.16)
Data are shown as mean (SD) of gene expression relative to endogenous control, eukaryotic 18S; pi Significant 2-way interaction effect of injection by sucrose; p < 0.05 (See Figures 5A and 6);
ω Significant 2-way interaction effect of EPA + DHA by sucrose; p < 0.0001; (See Figure 5B); # Significant main effect of injection; p < 0.05; Ω Significant main effect of EPA + DHA; p < 0.01.
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3.9. Effects of Sucrose, Omega-3 Fatty Acids, and Chemotherapy on Oxidative Stress, Anti-Oxidant Defense
and Lipid Peroxidation Markers in the Brain
In study 2, there were no differences in overall oxidative stress measured by Oxyblot assay,
anti-oxidant defense measured by SOD activity assay, or lipid peroxidation in brain tissue assayed by
4-HNE levels (p > 0.05 for all).
4. Discussion
In this model of postmenopausal chemotherapy, two injections of doxorubicin-based
chemotherapy induced significant neuroinflammation and reduced gene expression of dendritic
anchoring proteins essential to synaptic function, when compared to vehicle treatment. Dietary
enrichment with 2% kcal as EPA + DHA for five weeks resulted in higher brain DHA. Additionally,
in chemotherapy-treated mice, brain DHA was higher with low versus high sucrose diets. Beneficial
effects on gene expression of dendritic anchoring proteins in the cortex were seen with low sucrose and
EPA + DHA in diets. EPA + DHA enriched diets resulted in lower levels of specific neuroinflammatory
proteins in the cortex.
Our results support previous reports that doxorubicin-based chemotherapy causes significant
neuroinflammation [11,12]. Further, we found that chemotherapy-induced inflammation varied
depending on time since the last injection and the site of measurement (i.e., hippocampus, cortex or
serum). Regardless of the time point of tissue collection (i.e., 4, 7, or 14 days post-chemotherapy),
mice fed the 2% EPA + DHA diet had higher gene expression of cortical Shank 3, a member of a family of
anchoring proteins that is essential to synaptic formation, development, and function [34]. Ergo, Shank
3 expression contributes to brain plasticity. To our knowledge, this is the first report of a diet enriched
with EPA + DHA altering gene expression of a SHANK family protein. The functional significance
of this observation cannot be determined from the current study, but reduced Shank 3 expression has
been associated with autism-like behaviors, such as social deficits and stereotype [35,36].
Feeding sucrose during chemotherapy led to interesting effects on brain DHA.
In chemotherapy-treated mice only, brain DHA was significantly higher with low sucrose
versus high sucrose diets. As higher brain DHA has been associated with improved cognitive
performance in animal models [37], this dietary effect warrants further study. The fact that sucrose
only affected brain DHA in chemotherapy-treated mice suggests that high sucrose intake during
doxorubicin-based chemotherapy may be interacting to reduce DHA incorporation or increase
metabolism of DHA in the brain. Other researchers have reported that high sucrose diets resulted in
elevated levels of brain arachidonic acid in rats and increased activity of phospholipase A2 (PLA2)
enzymes, which are central to initiating metabolism of brain arachidonic acid and DHA by cleaving
PUFAs from phospholipid membranes [23]. We did not see significant differences in brain arachidonic
acid based on dietary sucrose alone, but we did find evidence that dietary sucrose in conjunction
with chemotherapy alters levels of other n-6 PUFAs in the brain (e.g., lowers linoleic acid and raises
arachidonic acid). Research suggests that doxorubicin may reduce activity of the DHA-preferring
isoform of PLA2 (i.e., iPLA2) and increase arachidonic acid [38,39]. Inhibition of iPLA2 could lead to
inability to repair damaged, oxidized lipids in membranes [40]. However, we did not find differences
in the lipid peroxidation or oxidative stress markers that we measured. Future research is needed to
clarify the effects of doxorubicin-based chemotherapy, n-3 PUFAs and sucrose on PUFA metabolites in
the brain.
Chemotherapy reduced gene expression of Shank 3 in the cortex, and increased protein levels of
inflammatory markers IL-5 and IL-6 in the hippocampus, compared to vehicle treatment. In contrast,
consumption of a 2% EPA + DHA diet had opposite effects: increasing Shank 3 gene expression and
reducing IL-6 protein levels in the cortex. Our study confirms previous reports that treatment with
doxorubicin and cytoxan increases IL-6 in serum of patients [41] and brains of rodents [16]. However,
both the chemotherapy and diet effects on Shank 3 gene expression are novel; while measures of
additional synaptic markers are warranted, our findings suggest that chemotherapy-induced deficits
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are partly mediated by detrimental changes in synaptic plasticity which can be attenuated by 2% EPA
+ DHA. Whether inflammation resulting from chemotherapy contributes to the observed decline in
Shank 3 is unknown, but a similar pattern of increased central nervous system IL-6 and decreased Shank
3 has been reported following exposure to air pollution [42]. In addition, we found beneficial changes
in the expression of the gene encoding for Shank 1 and Nfκ-β in mice fed low versus high sucrose
diets. High dietary sucrose has been linked to increased neuroinflammatory gene expression [43],
but modulation of SHANK family genes by dietary sucrose has not been previously reported. Together,
these data suggest that EPA + DHA and sucrose content of a diet may have effects on brain plasticity,
which is particularly crucial for individuals undergoing chemotherapy treatment.
We observed differential effects of chemotherapy and 2% EPA + DHA on neuroinflammation in
different regions of the brain. This could be related to the more “alert” or responsive phenotype of the
immune cells in the hippocampus compared to the cortex [44]. Indeed, we did find that chemotherapy
induced significant inflammation in the hippocampus but not the cortex 10 days after two injections.
Additionally, EPA + DHA reduced inflammation in the cortex, but not the hippocampus at this time
point. It is possible that region-specific differences in concentration of brain DHA also may have
contributed to differential effects, as research suggests that there is a greater proportion of DHA in
the cortex versus hippocampus of C57BL/6 mice [45]. We were unable to investigate this possibility
because we measured fatty acids using whole brain tissue and not distinct brain regions.
We found no significant differences in oxidative stress markers among diet or
chemotherapy-treated groups. In contrast, a recent report suggests that supplementation of
n-3 PUFAs alleviates doxorubicin-induced oxidative stress in male rats [16]. Our diverging results
could be related to differences in the model used, delivery of n-3 PUFAs (i.e., diet enrichment in our
study versus gavage by Wu and colleagues) or the dose and delivery of chemotherapy. Additionally,
our inability to detect significant differences in oxidative stress could be partially related to the
relatively high alpha linolenic acid (ALA) content of our No EPA + DHA control diet. While not
considered to be as anti-inflammatory as the longer chain, marine-derived n-3 PUFAs, ALA does
possess some anti-inflammatory properties [46] and is more efficiently converted to DHA by rodents
than humans [47]. Recently, researchers reported that a low sucrose diet enriched with ALA and fiber
countered the effects of high sucrose/high fat diet-induced obesity on spatial and short-term memory
in rats, and improved oxidative stress markers [47]. Future research should examine the effects of
a diet with various amounts of ALA and EPA + DHA on chemotherapy-induced neuroinflammation
and oxidative stress. Another promising area for future research centers on resolution of inflammation.
Specialized pro-resolving mediators (SPMs) of n-3 PUFAs, such as resolvins and protectins, have been
detected in the hippocampus of mouse models of lipopolysaccharide-induced inflammation and
humans with Alzheimer’s disease [48,49]. Future studies of SPMs in the context of chemotherapy
could add to our knowledge of mechanisms underlying nutritional modulation of neuroinflammation.
Strengths of this study include the measurement of central and peripheral inflammation at several
time points post-chemotherapy. In addition, the dose of EPA + DHA was comparable, as percentage
of energy, to high dose supplementation studies in breast cancer survivors and in women at high
risk for breast cancer [50,51], and similar to doses shown to reduce neuroinflammation [52,53] and
tumors [54] in mice. The sucrose doses were also designed to test effects across a range of intakes
physiologically relevant to humans [55]. Additionally, to make this research more translatable to the
human condition, the diets were formulated to avoid inducing an n-3 PUFA deficiency; the percentage
of energy provided by ALA in the control diets was approximately twice the median intake of U.S.
adults [56]. However, this is also a limitation because we did not include a diet low in total n-3 PUFAs,
which could have reduce our ability to detect differences between groups. Also, we were unable to
separate the effects of EPA from DHA in our studies. Finally, the use of relatively young healthy mice
that had not had tumors may have altered the physiological response to chemotherapy.
In conclusion, this research provided the first evidence that both chemotherapy and diet
influence of Shank gene expression, which may have implications for brain plasticity and function.
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Both low sucrose and EPA + DHA in the diet may attenuate neuroinflammation induced by
doxorubicin-based chemotherapy and protect proteins important in synaptic formation and function
in specific brain regions. Further research is needed to examine effects of dietary modification on
chemotherapy-induced cognitive deficits.
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